San Francisco, CA, United States of America

Daniel P Steiger

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 4.5

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2019-2022

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Daniel P. Steiger

Introduction

Daniel P. Steiger is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of biotechnology, particularly in the development of polypeptides with specific antigen-binding properties. With a total of 3 patents to his name, Steiger's work is paving the way for advancements in medical science.

Latest Patents

Steiger's latest patents include innovative applications related to insertable variable fragments of antibodies and modified A1-A2 domains of NKG2D ligands. These applications focus on the production of polypeptides that possess specific antigen-binding properties of Fv domains. His work not only addresses the insertable variable fragments of antibodies but also explores modified α1-α2 domains of NKG2D ligands. Furthermore, these applications delve into antigen-binding peptides derived from light and heavy chain antibody variable domains, which contain two linker regions and a split variable domain.

Career Highlights

Daniel P. Steiger is currently associated with Xyphos Biosciences Inc., where he continues to innovate and contribute to the field. His expertise in biotechnology and antibody engineering has positioned him as a key player in his organization.

Collaborations

Steiger collaborates with talented individuals such as Kyle Landgraf and Tarah Baron, enhancing the innovative capacity of his team.

Conclusion

Daniel P. Steiger's contributions to biotechnology through his patents and collaborations highlight his role as a significant inventor in the field. His work continues to influence advancements in medical science and antibody development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…